PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q2 2017 13F Holders as of 30 Jun 2017

Type / Class
Equity / COM
Total 13F shares
62,625,574
Share change
-2,132,411
Total reported value
$425,255,374
Put/Call ratio
117%
Price per share
$6.79
Number of holders
145
Value change
-$18,131,482
Number of buys
82
Number of sells
63

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q2 2017

As of 30 Jun 2017, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 145 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 62,625,574 shares. The largest 10 holders included FEDERATED INVESTORS INC /PA/, BlackRock Inc., VANGUARD GROUP INC, EAGLE ASSET MANAGEMENT INC, STATE STREET CORP, BAKER BROS. ADVISORS LP, FMR LLC, PINNACLE ASSOCIATES LTD, Phocas Financial Corp., and RICE HALL JAMES & ASSOCIATES, LLC. This page lists 145 institutional shareholders reporting positions in this security for the Q2 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.